Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3

Publisher： Karger

E-ISSN： 1423-0097|168|1|44-55

ISSN： 1018-2438

Source： International Archives of Allergy and Immunology, Vol.168, Iss.1, 2015-0, pp. : 44-55

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings

By  

International Archives of Allergy and Immunology, Vol. 173, Iss. 2, 2017-06 ,pp. : 114-119

Karger

Access to resources Recommend Favorite

Elevated D‐dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk

By  

ALLERGY, Vol. 70, Iss. 5, 2015-05 ,pp. : 506-513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial

By  

Psychotherapy and Psychosomatics, Vol. 81, Iss. 5, 2012-08 ,pp. : 312-314

Karger

Access to resources Recommend Favorite

Randomized, 8‐week, double‐blind, placebo‐controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52‐week open‐label extension trial

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 72, Iss. 2, 2018-02 ,pp. : 103-115

John Wiley & Sons Inc

Access to resources Recommend Favorite

Content Validity of Visual Analog Scales to Assess Symptom Severity of Acute Angioedema Attacks in Adults with Hereditary Angioedema: An Interview Study

By >  

The Patient: Patient-Centered Outcomes Research, Vol. 5, Iss. 2, 2012-06 ,pp. : 113-126

Adis International

Access to resources Recommend Favorite